News
ITCI
48.92
-1.65%
-0.82
Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $83 Price Target
Benzinga · 3d ago
Healthcare Outlook 2023
Seeking Alpha · 01/23 15:02
Analysts’ Top Healthcare Picks: Intra-Cellular Therapies (ITCI), Aadi Bioscience (AADI)
TipRanks · 01/17 13:20
RBC Capital Remains a Buy on Intra-Cellular Therapies (ITCI)
TipRanks · 01/17 01:45
--RBC Cuts Price Target on Intra-Cellular Therapies to $72 From $74, Maintains Outperform Rating
--RBC Cuts Price Target on Intra-Cellular Therapies to $72 From $74, Maintains Outperform Rating
MT Newswires · 01/13 08:11
BRIEF-Intra-Cellular Therapies Says Entered Into New Supply Agreement With Siegfried AG
Reuters · 01/09 22:32
Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish
Seeking Alpha · 01/09 14:55
Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), 2seventy bio (TSVT) and Privia Health Group (PRVA)
TipRanks · 01/09 04:21
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Intra-Cellular Therapies (ITCI)
TipRanks · 01/03 14:30
TG Therapeutics: Ramifications Of Briumvi Approval
Seeking Alpha · 01/02 18:04
Jefferies Reaffirms Their Buy Rating on Intra-Cellular Therapies (ITCI)
Tip Ranks · 12/27/2022 13:55
BRIEF-Intra-Cellular Therapies Inc- On Dec 19, Co's Unit, ITI Limited Entered Amendment No.1 To Master Services Agreement Dated As Of January 10, 2017
Reuters · 12/22/2022 21:15
Insider Sell: Intra-Cellular Therapies
Insider Sell: Intra-Cellular Therapies
MT Newswires · 12/21/2022 16:11
Intra-Cellular Therapies Highlights New CAPLYTA Bipolar Depression Data Presentations at the American College of Neuropsychopharmacology 61st Annual Meeting
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced four data pr...
GlobeNewswire · 12/08/2022 13:00
Intra-Cellular Therapies Has My Attention
Intra-Cellular-Therapies develops treatments for people with neuropsychiatric and neurologic disorders like their medicine for bipolar disease. Let's check out the charts and indicators. In this daily bar chart of ITCI, below, we can see an improving p...
TheStreet.com · 11/30/2022 15:28
Is DICE Therapeutics (DICE) Outperforming Other Medical Stocks This Year?
Here is how DICE Therapeutics, Inc. (DICE) and Intra-Cellular Therapies (ITCI) have performed compared to their sector so far this year.
Zacks · 11/30/2022 14:40
Is Intra-Cellular Therapies (ITCI) Stock a Worthy Buy?
ClearBridge Investments, an investment management company, published its “ClearBridge Small Cap Growth Strategy” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the strategy underperformed its benchmark,...
Insider Monkey · 11/27/2022 02:00
More
Webull provides a variety of real-time ITCI stock news. You can receive the latest news about Intra Cellular through multiple platforms. This information may help you make smarter investment decisions.
About ITCI
Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company provides CAPLYTA (lumateperone) for the treatment of schizophrenia in adults. The CAPLYTA is a prescription medicine used to treat the depressive episodes in adults with bipolar I or II, that can be taken alone or with lithium or valproate. The Company's pipeline is focused on three platforms: lumateperone and follow-on compounds, a phosphodiesterase 1 (PDE1) inhibitor platform and discovery platform which includes ITI-333 a novel compound with high affinity at serotonin 5-HT2A, dopamine D1 and mu opioid (MOP) receptors. The Company’s subsidiaries are ITI, Inc. (ITI) and ITI Limited.